Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Hypertension Monotherapy or in combination with other antihypertensive agents: As levamlodipine maleate/besylate: Initial: 2.5 mg once daily. Angina pectoris As levamlodipine besylate: 2.5 mg once daily. All doses may be increased as necessary according to patient response. Max: 5 mg once daily.
Dosage Details
Adult: As monotherapy or in combination with other antihypertensive agents: As levamlodipine maleate/besylate: Initially, 2.5 mg once daily, may increase dose (or titrate every 1-2 weeks for maleate) as necessary according to patient response. Max: 5 mg once daily.
Child: 6-17 years As levamlodipine maleate: 1.25-2.5 mg once daily.
Elderly: As levamlodipine maleate: Initially, 1.25 mg once daily, may titrate every 1-2 weeks as necessary according to patient response.

Angina pectoris
Adult: As levamlodipine besylate: 2.5 mg once daily, may be increased up to 5 mg once daily if necessary.
Hepatic Impairment
Hypertension: As levamlodipine maleate: Initially, 1.25 mg once daily, may be titrated slowly for severe impairment.
Special Precautions
Patient with severe aortic stenosis; severe obstructive coronary artery disease, heart failure with reduced ejection fraction, hypertrophic cardiomyopathy and outflow tract obstruction. Hepatic impairment. Children and elderly. Pregnancy and lactation.
Adverse Reactions
Significant: Worsening angina, acute MI, reflex tachycardia, symptomatic hypotension.
Cardiac disorders: Dyspnoea, palpitation.
Gastrointestinal disorders: Nausea, abdominal pain.
General disorders and administration site conditions: Fatigue, asthenia.
Hepatobiliary disorders: Jaundice.
Investigations: Increased liver enzymes.
Metabolism and nutrition disorders: Peripheral oedema.
Musculoskeletal and connective tissue disorders: Muscle cramps.
Nervous system disorders: Dizziness, extrapyramidal disorder.
Psychiatric disorders: Somnolence, insomnia.
Reproductive system and breast disorders: Sexual dysfunction, gynaecomastia.
Skin and subcutaneous tissue disorders: Rash, pruritus.
Vascular disorders: Flushing.
Monitor heart rate and blood pressure.
Symptoms: May be related to racemic amlodipine including excessive peripheral vasodilation, marked hypotension, reflex tachycardia. Management: In case of large overdose, monitor cardiac and respiratory function and perform gastric lavage. Monitor blood pressure. For hypotension, initiate CV support including elevation of extremities and administration of fluids. Consider administration of vasopressors (e.g. phenylephrine) in case hypotension remains unresponsive.
Drug Interactions
May increase serum concentrations with moderate and strong CYP3A4 inhibitors. May increase the serum levels of simvastatin, lovastatin, immunosuppressants (e.g. ciclosporin, tacrolimus).
Lab Interference
May result to false-negative aldosterone/renin ratio (ARR).
Description: Levamlodipine, a dihydropyridine Ca channel blocker, is the pharmacologically active antihypertensive isomer of amlodipine. It reduces peripheral vascular resistance and blood pressure by directly inhibiting Ca ion transmembrane influx into vascular smooth muscles and to a lesser extent into cardiac muscle cells.
Synonym: (S)-amlodipine.
Onset: Gradual.
Duration: ≥24 hours.
Absorption: Bioavailability: 64-90%. Time to peak plasma concentration: 6-12 hours.
Distribution: Plasma protein binding: Approx 93%.
Metabolism: Extensively metabolised in the liver (approx 90%) to form inactive metabolites.
Excretion: Via urine (10% as unchanged drug, 60% as metabolites). Elimination half-life: Approx 14.62-68.88 hours.
Chemical Structure

Click on icon to see table/diagram/image
Store between 15-30°C.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Levamlodipine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in